var data={"title":"Pyridostigmine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pyridostigmine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6878?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pyridostigmine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pyridostigmine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pyridostigmine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pyridostigmine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215907\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mestinon;</li>\n      <li>Regonol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215908\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mestinon;</li>\n      <li>Mestinon-SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215948\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Acetylcholinesterase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215911\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Highly individualized dosing ranges:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release: 60 to 1,500 mg/day, usually 600 mg/day divided into 5 to 6 doses, spaced to provide maximum relief</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained release: 180 to 540 mg once or twice daily (doses separated by at least 6 hours); <b>Note:</b> It may be necessary to use immediate-release therapy in conjunction with sustained-release therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV (off-label use): To supplement during labor and postpartum, during myasthenic crisis, or when oral therapy is impractical: ~1/30th of oral dose; observe patient closely for cholinergic reactions. IM route preferred due to significant complications (eg, cardiac arrest) observed with the IV route (Maggi 2011; Varner 2013). May also administer as a continuous infusion for myasthenic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion:</i> IV: 1 to 2 mg/hour with gradual titration in increments of 0.5 to 1 mg/hour, up to a maximum rate of 4 mg/hour (Berrouschot 1997; Saltis 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of nondepolarizing muscle relaxants:</b> IV: 0.1 to 0.25 mg/kg/dose (onset to peak effect is dose-dependent; return of twitch height to 90% of control occurs within ~6 minutes; full recovery usually occurs within 15 to 30 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The monitoring of muscle twitch response to peripheral nerve stimulation is advised; administer pyridostigmine after spontaneous recovery of neuromuscular function has begun. Atropine sulfate or glycopyrrolate IV should be administered immediately prior to or simultaneously with pyridostigmine to minimize side effects. Inadequate reversal is possible; manage by manual or mechanical ventilation until recovery is judged adequate (additional doses are not recommended).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Soman nerve gas exposure, pretreatment (military use):</b> <b>Note:</b> Do not administer pyridostigmine after Soman exposure; if taken immediately before exposure (eg, when gas attack alarm is given) or at the same time, it is not expected to be effective and may exacerbate the effects of a sub-lethal exposure to Soman.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 30 mg every 8 hours beginning several hours prior to exposure; discontinue at first sign of Soman exposure, then immediately begin atropine and pralidoxime.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Disopyramide-induced anticholingeric adverse effects (off-label use): </b>Oral: Sustained release: 90 to 180 mg every 12 hours or as needed (Sherrid 2013; Sherrid 2016; Teichman 1987)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215928\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pyridostigmine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pyridostigmine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Myasthenia gravis (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Limited data available; dosage should be adjusted such that larger doses administered prior to time of greatest fatigue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Immediate release: 1 mg/kg/dose every 4 to 6 hours; maximum daily dose: 7 mg/kg/day divided in 5 to 6 doses; (Usual daily dose: 600 mg/day; doses as high as 1,500 mg/day have been used) (Andrews 1998; Maggi 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM, IV: 0.05 to 0.15 mg/kg/dose (maximum dose: 10 mg) (Kleigman 2007). IM route preferred due to significant complications (eg, cardiac arrest) observed with the IV route (Maggi 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215912\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215913\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, lower initial doses dosages may be required due to prolonged elimination in renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22548559\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215882\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Regonol: 10 mg/2 mL (2 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mestinon: 60 mg/5 mL (473 mL) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, sodium benzoate; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mestinon: 60 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mestinon: 180 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 180 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215867\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215885\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Do <b>not</b> crush extended release tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For myasthenic crisis (off-label use), may administer IM, slow IV push, or as a continuous infusion (Maggi 2011; Saltis 1993).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215884\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis (oral only):</b> Treatment of myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Reversal of nondepolarizing muscle relaxants (injection only):</b> Reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Military use:</b> Pretreatment for Soman nerve gas exposure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27261185\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Disopyramide-induced anticholingeric adverse effects; Myasthenia gravis (IM, IV use); Additional Off-label uses:</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215957\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pyridostigmine may be confused with physostigmine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Regonol may be confused with Reglan, Renagel</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215873\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Twitching (3%), hyperesthesia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Xeroderma (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (7%), diarrhea (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysmenorrhea (5%), urinary frequency (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (2%), neck pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Amblyopia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (transient), chest tightness, decreased heart rate, increased blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion, depressed mood, disturbed sleep, drowsiness, headache, hypertonia, lack of concentration, lethargy, localized warm feeling, numbness of tongue, tingling of extremities, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, diaphoresis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, bloating, borborygmi, flatulence, increased peristalsis, nausea, salivation, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Fasciculations, muscle cramps, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye pain, lacrimation, miosis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute bronchitis (exacerbation), exacerbation of asthma, increased bronchial secretions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Fecal incontinence, loss of consciousness, pallor (postsyncopal), stiffness (arms or upper torso), thrombophlebitis, urinary incontinence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215888\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to pyridostigmine, anticholinesterase agents, or any component of the formulation; mechanical intestinal or urinary obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for anticholinergic muscle stimulants is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215871\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholinergic effects: Symptoms of excess cholinergic activity may occur (eg, salivation, sweating, urinary incontinence). Overdosage may result in cholinergic crisis (eg, muscle weakness), which must be distinguished from myasthenic crisis; discontinue immediately in the presence of cholinergic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: May occur; have atropine and epinephrine ready to treat hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with bradycardia or other cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution; additive effect with antiglaucoma drugs may cause or exacerbate problems with night vision.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; initial lower doses may be needed; titrate to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with extreme caution in patients with asthma, bronchospastic disease, or COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bromide sensitivity: Use with caution in patients with bromide sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Injection not indicated for use in neonates; may contain benzyl alcohol which has been associated with &quot;gasping syndrome&quot; in neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Must be administered by trained personnel; use of peripheral nerve stimulation to monitor neuromuscular function recovery and continuous patient observation until recovery of normal respiration is recommended. To counteract anticholinergic effects, use of glycopyrrolate or atropine sulfate simultaneously with or prior to administration is recommended. May contain benzyl alcohol which has been associated with &quot;gasping syndrome&quot; in neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral: Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inadequate reversal of nondepolarizing muscle relaxants: Inadequate reversal induced by nondepolarizing muscle relaxants is possible; manage with manual or mechanical ventilation until recovery is adequate (additional doses not recommended). Failure to produce prompt (within 30 minutes) reversal of neuromuscular blockade may occur in the presence of extreme debilitation, carcinomatosis, or with concomitant use of certain broad-spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular blockade or cause respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Military use: Only for pretreatment for exposure to Soman; discontinue pyridostigmine at the first sign of Soman exposure (do not administer pyridostigmine after Soman exposure); atropine and pralidoxime must be administered after Soman exposure (pyridostigmine pretreatment offers no benefit against Soman unless atropine and pralidoxime are administered once symptoms of poisoning appear). Use in conjunction with protective garments, including gas mask, hood and overgarments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299967\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215875\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9838&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methocarbamol: May diminish the therapeutic effect of Pyridostigmine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215878\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (manufacturer dependent) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215891\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Pyridostigmine may cross the placenta (Buckley 1968). Use of pyridostigmine may be continued during pregnancy for the treatment of myasthenia gravis (Norwood 2013; Skie 2010) and its use should be continued during labor (Norwood 2013). Transient neonatal myasthenia gravis may occur in 10% to 20% of neonates due to placental transfer of maternal antibodies (Skie 2010; Varner 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215892\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyridostigmine is excreted in breast milk (Hardell 1992). The manufacturer recommends that caution be exercised when administering pyridostigmine to nursing women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Information is available from two mothers using pyridostigmine for myasthenia gravis throughout pregnancy and postpartum. Maternal doses ranged from 180 mg to 300 mg/day. Milk concentrations averaged &le;0.1% of the weight adjusted maternal dose (n=2); infant plasma concentrations were less than the limit of quantification (&lt;2 ng/mL; n=1) (Hardell 1992). Disease exacerbations may occur in nursing women with poorly controlled myasthenia gravis due to fatigue associated with breast-feeding. Babies born to women with myasthenia gravis may have feeding difficulties due to transient myasthenia gravis of the newborn (Norwood 2013). Nursing infants should be monitored for fatigue associated with transient neonatal myasthenia gravis (Varner 2013), however current guidelines note that nursing is not contraindicated in women taking pyridostigmine for myasthenia gravis (Norwood 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215880\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, blood pressure, and heart rate especially with IV use; observe for cholinergic reactions (eg, nausea, vomiting, diarrhea, increased salivation), particularly when administered IV; consult individual institutional policies and procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215870\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across neuromuscular junction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215887\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recovery from vincristine neurotoxicity: Onset of action: 1 to 2 weeks (Akbayram 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myasthenia gravis: Oral: Within 30 minutes (Maggi 2011); IM: 15 to 30 minutes; IV: Within 2 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: 3 to 4 hours in the daytime (Maggi 2011); IM, IV: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Very poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.53 to 1.76 L/kg (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein Binding: None (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and at tissue site by cholinesterases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 10% to 20% (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 1 to 2 hours; renal failure: ~6 hours (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: ~1.5 hours (Aquilonius 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 1 to 2 hours (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% to 90% as unchanged drug) (Aquilonius 1986)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215890\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Regonol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $32.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Mestinon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/5 mL (473 mL): $1,404.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Mestinon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $983.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Pyridostigmine Bromide ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $744.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mestinon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,728.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pyridostigmine Bromide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $127.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215893\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amygra (PK);</li>\n      <li>Antilon (TW);</li>\n      <li>Astinon (PH);</li>\n      <li>Brostagin (PL);</li>\n      <li>Distinon (IN);</li>\n      <li>Dosmin (KR);</li>\n      <li>Dostimid (BD);</li>\n      <li>Kalimin (UA);</li>\n      <li>Kalymin (BG, DE, EE, LV, RU, TR);</li>\n      <li>Meshanon (VN);</li>\n      <li>Mestinon (AE, AR, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CL, CO, CY, CZ, DK, EG, ES, FI, FR, GB, GH, GR, GY, HK, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LK, LU, LY, MT, MX, MY, NO, OM, PE, PH, PL, PT, PY, QA, SA, SE, SG, SI, SK, SR, SY, TH, TR, TT, TW, TZ, UG, UY, VE, YE, ZM);</li>\n      <li>Mestinon Retard (NL);</li>\n      <li>Mestinon Timespan (BB);</li>\n      <li>Pyrido (LK);</li>\n      <li>Pyrimine (TH);</li>\n      <li>Pyrinol (KR);</li>\n      <li>Pyrinon (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akbayram S, Akgun C, Do&#287;an M, et al, &quot;Use of Pyridoxine and Pyridostigmine in Children With Vincristine-Induced Neuropathy,&quot; <i>Indian J Pediatr</i>, 2010, 77(6):681-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aquilonius SM and Hartvig P, &quot;Clinical Pharmacokinetics of Cholinesterase Inhibitors,&quot; <i>Clin Pharmacokinet</i>, 1986, 11(3):236-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/3524957/pubmed\" target=\"_blank\" id=\"3524957\">3524957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9233752\"></a>Berrouschot J, Baumann I, Kalischewski P, et al. Therapy of myasthenic crisis. <i>Crit Care Med</i>. 1997;25(7):1228-1235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/9233752/pubmed\" target=\"_blank\" id=\"9233752\">9233752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckley GA, Roberts DV, Roberts JB, Thomas BH, Wilson A. Drug-induced neonatal myasthenia. <i>Br J Pharmacol</i>. 1968;34(1):203P-204P.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/5692081/pubmed\" target=\"_blank\" id=\"5692081\">5692081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunn MA, Sidell FR. Progress in medical defense against nerve agents. <i>JAMA</i>. 1989;262(5):649-652. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/2664236/pubmed\" target=\"_blank\" id=\"2664236\">2664236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hardell LI, Lindstr&ouml;m B, L&ouml;nnerholm G, Osterman PO. Pyridostigmine in human breast milk. <i>Br J Clin Pharmacol</i>. 1982;14(4):565-567.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/7138742/pubmed\" target=\"_blank\" id=\"7138742\">7138742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. <i>JAMA</i>. 1991;266(5):693-695.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/2072481/pubmed\" target=\"_blank\" id=\"2072481\">2072481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21815707\"></a>Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. <i>Clin Drug Investig</i>. 2011;31(10):691-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/21815707/pubmed\" target=\"_blank\" id=\"21815707\">21815707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mestinon (pyridostigmine) [prescribing information]. Bridgewater, NJ: Valeant; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(5):538-543.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/23757420/pubmed\" target=\"_blank\" id=\"23757420\">23757420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regonol (pyridostigmine) [prescribing information]. Princeton, NJ: Sandoz; July 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8504663\"></a>Saltis LM, Martin BR, Traeger SM, Bonfiglio MF. Continuous Infusion of pyridostigmine in the management of myasthenic crisis. <i>Crit Care Med</i>. 1993;21(6):938-940.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/8504663/pubmed\" target=\"_blank\" id=\"8504663\">8504663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26818487\"></a>Sherrid MV. Drug therapy for hypertrophic cardiomyopathy: physiology and practice. <i>Curr Cardiol Rev</i>. 2016;12(1):52-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/26818487/pubmed\" target=\"_blank\" id=\"26818487\">26818487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23704138\"></a>Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with &beta;-blockade or verapamil. <i>Circ Heart Fail</i>. 2013;6(4):694-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/23704138/pubmed\" target=\"_blank\" id=\"23704138\">23704138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sidell FR, Borak J. Chemical warfare agents: II. Nerve agents. <i>Ann Emerg Med</i>. 1992;21(7):865-871. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/1610046/pubmed\" target=\"_blank\" id=\"1610046\">1610046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skeie GO, Apostolski S, Evoli A, et al; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. <i>Eur J Neurol</i>. 2010;17(7):893-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/20402760/pubmed\" target=\"_blank\" id=\"20402760\">20402760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3624669\"></a>Teichman SL, Ferrick A, Kim SG, et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. <i>J Am Coll Cardiol</i>. 1987;10(3):633-641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/3624669/pubmed\" target=\"_blank\" id=\"3624669\">3624669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varner M. Myasthenia gravis and pregnancy. <i>Clin Obstet Gynecol</i>. 2013;56(2):372-381. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/23563874/pubmed\" target=\"_blank\" id=\"23563874\">23563874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26684556\"></a>Verlinden NJ, Coons JC. Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. <i>Pharmacotherapy</i>. 2015;35(12):1164-1172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-drug-information/abstract-text/26684556/pubmed\" target=\"_blank\" id=\"26684556\">26684556</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9838 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F215907\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F215908\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F215948\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F215911\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F215928\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F215912\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F215913\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22548559\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215882\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F215867\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F215885\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F215884\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27261185\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F215957\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215873\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215888\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215871\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299967\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215875\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215878\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F215891\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F215892\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F215880\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215870\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F215887\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215890\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F215893\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9838|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pyridostigmine-patient-drug-information\" class=\"drug drug_patient\">Pyridostigmine: Patient drug information</a></li><li><a href=\"topic.htm?path=pyridostigmine-pediatric-drug-information\" class=\"drug drug_pediatric\">Pyridostigmine: Pediatric drug information</a></li></ul></div></div>","javascript":null}